Drugs / CD56+CD3- NK cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01386619 | Jan 2004 → Mar 2011 | acute myeloid leukemia, lymphoma, myelodysplastic syndrome, neuroblastoma +2 | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1/2 | NCT01220544 | Jul 2001 → Oct 2010 | acute myeloid leukemia, disease related to hematopoietic stem cell transplant | Charite University, Berlin, Germany | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD56+CD3- NK cells | “A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.” NCT01220544 ↗ |
| Known as | CD3-depleted/CD56+ selected natural killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01386619 ↗ |
| Modality | Cell therapy | “Aim of the study is to evaluate cellular therapy with alloreactive, IL-2 activated NK cells after transplantation of T-cell depleted stem cell grafts” NCT01220544 ↗ |